Pharma
Veeva Systems just released its first AI agents, bringing automated capabilities to its Vault CRM and PromoMats. The company says that the agents work inside existing applications, have direct access to data and workflows, and operate within established permissions and audit trails.
Veeva’s rollout marks a shift from discrete AI features to workflow-embedded automation, arriving as regulators in the United States and Europe formalize expectations for credible and transparent artificial intelligence in drug development.
“With industry-specific Veeva AI Agents working seamlessly in Veeva applications, the life sciences industry can increase productivity, customer centricity, and advance to new ways of working,” said Andy Han, senior vice president of Veeva AI. The company’s claims that embedding agents inside validated systems offers a compliance advantage at a moment of rising regulatory scrutiny.
Architecture Built for Embedded AI
The introduction of AI agents continues a multi-year shift toward consolidating regulated data and workflows on the Vault Platform. Veeva has emphasized this direction since the early 2010s, describing Vault as a unified foundation for structured data, content, and workflow management. Over time the company replaced earlier CRM products delivered on Salesforce infrastructure with Vault-native modules, giving Veeva direct control of the data layer and the surrounding validation environment. That control is now central to its AI strategy.
